NR4A1 and breast carcinoma: Additionally, specific patients are excluded: patients with B&R grade 1 hormone receptor positive breast cancer are excluded because of the poor NAC treatment results that have been reached for this subtype, and the proposed systemic treatment de-escalation prescribed in current guidelines.